NCT05358340 Dual Perfusion Imaging for Characterizing Vascular Architecture of Brain Lesions Status UNKNOWN Phase NA
NCT05346367 Improving Therapeutic Ratio With Hypo Fractionated Stereotactic Radiotherapy for Brain Metastases Status RECRUITING Phase NA
NCT05323955 Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT05305365 Study Assessing QBS72S For Treating Brain Metastases Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT05255666 Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM) Status WITHDRAWN Phase PHASE2
NCT05241873 (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations Status TERMINATED Phase PHASE1
NCT05207904 Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced Squamous NSCLC With Brain Metastases Status UNKNOWN Phase PHASE2
NCT05185557 BRIANSTORM - Early Identification of Patients With Brain Metastases Status UNKNOWN Phase N/A
NCT05177185 Hippocampal-Sparing Stereotactic Radiosurgery Treatment of Brain Metastases Using CyberKnife Status UNKNOWN Phase PHASE2
NCT05160818 Hypofractionated Versus Single Fraction Stereotactic Adjuvant Radiotherapy to the Resection Cavity of Brain Metastases Status UNKNOWN Phase NA
NCT05146219 Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation Status COMPLETED Phase PHASE2
NCT05064280 Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases Status RECRUITING Phase PHASE2
NCT05054400 Study of Laser Interstitial Thermal Therapy (LITT) Treatment Response Assessment With Fluciclovine PET MR Status WITHDRAWN Phase EARLY_PHASE1
NCT05048212 A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases Status RECRUITING Phase PHASE2
NCT05045950 Optimizing Neurocognition With Whole Brain Radiation Therapy (WBRT) Using Upfront Pulsed Reduced Dose-Rate (PRDR) Technique Status RECRUITING Phase PHASE2
NCT05033691 A Study to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients With EGFR Mutated NSCLC and Asymptomatic Brain Metastases Status RECRUITING Phase NA